LIFR and liver cancer: Recently, Yao et al. reported that leukemia inhibitory factor receptor (LIFR) is frequently downregulated in liver cancer and its loss provokes liver tumorigenesis and confers resistance to drug-induced ferroptosis, as well as to erastin and RSL3 [348].